Literature DB >> 17399959

Fronto-temporal-lobe atrophy in early-stage Alzheimer's disease identified using an improved detection methodology.

Tom F D Farrow1, Subha N Thiyagesh, Iain D Wilkinson, Randolph W Parks, Leanne Ingram, Peter W R Woodruff.   

Abstract

Alzheimer's disease (AD) is associated with widespread brain atrophy including structures subserving memory. We applied an improved structural detection methodology to examine the less well known progression of atrophy in early-stage AD. We sought to i) longitudinally study volumetric differences in patients with early-stage AD and healthy volunteers; and ii) test the hypothesis that hippocampal volumes would be correlated with clinically relevant cognitive function. Seven patients and eleven healthy subjects underwent two structural MRI scans and neuropsychological assessments. Scans were normalised to a study-specific template and 'morphologically opened' to reduce tissue misclassification. Using brain-parcellation, patient atrophy was localised to left fusiform and parahippocampal gyri, whilst left hippocampal volumes were correlated with a cognitive performance measure. A whole-brain search methodology, showed that patients had reduced volumes including fronto-temporal regions bilaterally, in hippocampi and amygdalae and right cerebellum. Whole-brain correlational analyses revealed that cognitive performance was correlated with volumes of both hippocampi, superior temporal gyri and left insula. Neither group exhibited significant longitudinal volumetric changes. Utilising a novel methodology, we have shown that in early-stage AD, clinically relevant cognitive deficits are correlated with regionally specific grey-matter volumes, which are detectable at an early stage of the illness.

Entities:  

Mesh:

Year:  2007        PMID: 17399959     DOI: 10.1016/j.pscychresns.2006.12.013

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  13 in total

Review 1.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

2.  Removing inter-subject technical variability in magnetic resonance imaging studies.

Authors:  Jean-Philippe Fortin; Elizabeth M Sweeney; John Muschelli; Ciprian M Crainiceanu; Russell T Shinohara
Journal:  Neuroimage       Date:  2016-02-23       Impact factor: 6.556

Review 3.  Atrophy: When too much atrophy is too little brain.

Authors:  Charles A J Romanowski; Iain D Wilkinson
Journal:  Neuroradiology       Date:  2011-09       Impact factor: 2.804

4.  Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity.

Authors:  Stéphane P Poulin; Rebecca Dautoff; John C Morris; Lisa Feldman Barrett; Bradford C Dickerson
Journal:  Psychiatry Res       Date:  2011-09-14       Impact factor: 3.222

Review 5.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

6.  Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease.

Authors:  Rukhsana Sultana; Marzia Perluigi; Shelley F Newman; William M Pierce; Chiara Cini; Raffaella Coccia; D Allan Butterfield
Journal:  Antioxid Redox Signal       Date:  2010-03       Impact factor: 8.401

7.  Cerebellar Grey Matter Volume in Older Persons Is Associated with Worse Cognitive Functioning.

Authors:  A Buhrmann; A M A Brands; J van der Grond; C Schilder; R C van der Mast; N Rius Ottenheim; J C Foster-Dingley; A S Bertens; E van den Berg
Journal:  Cerebellum       Date:  2021-02       Impact factor: 3.847

8.  Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.

Authors:  Benjamin M Doherty; Stephanie A Schultz; Jennifer M Oh; Rebecca L Koscik; N Maritza Dowling; Todd E Barnhart; Dhanabalan Murali; Catherine L Gallagher; Cynthia M Carlsson; Barbara B Bendlin; Asenath LaRue; Bruce P Hermann; Howard A Rowley; Sanjay Asthana; Mark A Sager; Brad T Christian; Sterling C Johnson; Ozioma C Okonkwo
Journal:  Alzheimers Dement (Amst)       Date:  2015-06-01

9.  Altered Functional Connectivity of the Basal Nucleus of Meynert in Mild Cognitive Impairment: A Resting-State fMRI Study.

Authors:  Hui Li; Xiuqin Jia; Zhigang Qi; Xiang Fan; Tian Ma; Hong Ni; Chiang-Shan R Li; Kuncheng Li
Journal:  Front Aging Neurosci       Date:  2017-05-04       Impact factor: 5.750

10.  Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.

Authors:  Ming Tong; Cesar Dominguez; John Didsbury; Suzanne M de la Monte
Journal:  J Alzheimers Dis Parkinsonism       Date:  2016-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.